Health Care/Hospital
Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%
SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...
2021-10-29 17:17
1376
SEI & Medtrics partnership: Bringing telemedicine service to Android TV
SHENZHEN, China, Oct. 29, 2021 /PRNewswire/ -- SEI Robotics Inc, a global innovator of smart IOT devices & provider of Android TV platforms for Pay-TV operators (MVPD), announced its strategic partnership with Medtrics Inc, The Silicon Valley startup, leader of the digital health service speci...
2021-10-29 16:30
1308
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report
Highlights: * New details on ATH34 Phase 2 clinical trial released. * Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. * Expanded intellectual property portfolio positions future opportunities. * Cash balance as of 30 September 2021 of A$41.3M....
2021-10-29 14:50
2184
IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA
SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, which will begin soon in the U.S. This will be the first in human study for the A...
2021-10-29 14:12
1469
Exosystems Raises $3.9M Series A Funding, on Mission to Provide AI-based Digital Care for Musculoskeletal System
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Exosystems, an artificial intelligence (AI)-based digital healthcare company and a member ofBorn2Global Centre, has succeeded in attracting Series A funding worth USD 3.9 million from SBI Investment, Laguna Investment, and Korea Technology Finance...
2021-10-29 07:47
1440
Osfirm to Launch Novel Implantable Biomaterial Whitlockite with Excellent Biodegradability and Bone Regenerative and Reconstructive Properties into Global Market by the Year 2023
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In 1941, "whitlockite," the second most abundant inorganic mineral of the bone was named in honor of Herbert Whitlockite, Curator of Minerals and Gems in the American Museum of Natural History inNew York. Whitlockite is a unique form of magnesium ...
2021-10-28 21:00
1118
Jubilee Biotech has developed JUBIwatch, "Health and Life are now wearable"
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Jubilee Biotech, a startup in South Korea, has developed JUBIwatch, a smart watch and medication management platform that uses microneedles to administer exact amounts of medication at set times. "Wearing, setting up, and sending information on m...
2021-10-28 21:00
1118
HanAll Biopharma Reports Third Quarter 2021 Results
* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...
2021-10-28 21:00
1445
Aiming for Global CDMO, Xcell Therapeutics opens an export route to 62 countries with cell therapy culture technology.
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resembles the papilla of the human body when observed under a microscope. Hair loss occurs when der...
2021-10-28 21:00
1188
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility
- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...
2021-10-28 08:30
1880
Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults
– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global ...
2021-10-28 05:48
2110
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 20:47
1029
Waterdrop Inc offers Huiminbao services to raise insurance coverage for China's underserved consumer population
BEIJING, Oct. 27, 2021 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or "the Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, has taken a leading position in the government-backed health insurance product (known as "Hu...
2021-10-27 15:47
2227
Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production
JIUQUAN, China, Oct. 26, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company has completed phase one of the expansion of its new organic fertilizer produc...
2021-10-26 20:00
1432
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China
* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...
2021-10-26 20:00
1987
Medigate Launches Clinical Device Efficiency to Improve Operational Efficiency for HDOs
The new offering from the medical device cybersecurity leader aims to increase medical device visibility, streamline hospital workflows, and reduce costs BROOKLYN, N.Y., Oct. 26, 2021 /PRNewswire/ -- Medigate, creator of the industry's first and leading healthcare-specific platform to orchestrate...
2021-10-26 20:00
1201
Samsung Biologics Reports Third Quarter 2021 Financial Results
* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...
2021-10-26 15:23
1655
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...
2021-10-26 07:30
1426
Wellspring Capital Management Acquires Caring Brands International
SUNRISE, Fla., Oct. 25, 2021 /PRNewswire/ -- Wellspring Capital Management ("Wellspring"), a leading private equity firm headquartered inNew York, announced today that it has partnered with management to complete the acquisition of Caring Brands International, Inc. ("CBI" or the "Company"). Term...
2021-10-25 23:00
1831
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...
2021-10-25 20:30
1548
Week's Top Stories
Most Reposted
2024 Malaysia E-Commerce Product Selection Expo Attracts International Delegations
[Picked up by 313 media titles]
2024-12-02 12:06
AC Health makes critical HIV care more accessible to Filipinos with USAID support
[Picked up by 298 media titles]
2024-12-03 16:11
ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 298 media titles]
2024-11-28 17:24Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 288 media titles]
2024-11-29 20:33
Hong Kong Airlines Resumes Vancouver Service Offering Twice-weekly direct flights from 18 January 2025
[Picked up by 287 media titles]
2024-12-02 20:01
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
9953
China's spicy hotpot sets its sights on global market
2024-11-29 21:36
4334
CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
2024-11-30 09:00
4310